Physician profile
Yasar Torres-Yaghi
NPI 1720379951
$968,832.95
in general payments reported to CMS, 2019-2025
39 companies · $137K in 2025
The $137K reported for 2025 was more than what 99% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $180K · 2020: $180K · 2021: $158K · 2022: $115K · 2023: $101K · 2024: $98K · 2025: $137K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $176K · Consulting Fee: $87K · Honoraria: $39K · Food and Beverage: $19K · Travel and Lodging: $8,031 · Education: $5,840.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $176,203.38 |
| Consulting Fee | $86,675.50 |
| Honoraria | $39,376.00 |
| Food and Beverage | $19,187.72 |
| Travel and Lodging | $8,031.01 |
| Education | $5,839.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amneal Pharmaceuticals LLC | $235,637.92 | 2019-2025 | Crexont, Rytary, Ongentys 50mg Capsules 30 |
| Acorda Therapeutics, INC | $120,151.36 | 2019-2024 | Inbrija, Ampyra |
| Kyowa Kirin, INC. | $98,970.13 | 2019-2024 | Nourianz |
| Acadia Pharmaceuticals INC | $98,220.44 | 2019-2025 | Nuplazid |
| Abbvie INC. | $89,257.77 | 2019-2025 | Duopa, Botox, Ubrelvy |
| Teva Pharmaceuticals USA, INC. | $84,136.54 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Mdd US Operations, LLC | $58,781.97 | 2019-2025 | Apokyn, Gocovri, Apokyn |
| Lilly USA, LLC | $50,532.03 | 2019-2025 | Kisunla, Amyvid |
| Biogen, INC. | $41,856.89 | 2020-2025 | Leqembi |
| Sunovion Pharmaceuticals INC. | $27,588.58 | 2019-2022 | |
| Corium, LLC | $19,997.12 | 2023 | Adlarity, Azstarys |
| Tanabe Pharma America, INC. | $8,250.00 | 2023-2025 | |
| Adamas Pharmaceuticals, INC. | $7,264.54 | 2019-2021 | |
| Merz Pharmaceuticals, LLC | $6,502.83 | 2022-2025 | Xeomin, Inbrija |
| Neurocrine Biosciences, INC. | $5,344.01 | 2022-2025 | Ongentys, Ingrezza |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kyowa Kirin Co., Ltd | $5,130.00 | 2024 | Nourianz |
| Ge Healthcare | $3,328.57 | 2024-2025 | |
| Abbott Laboratories | $2,732.64 | 2019-2025 | Infinity |
| Allergan, INC. | $984.32 | 2019-2022 | |
| Medtronic USA, INC. | $904.61 | 2019 | |
| Revance Therapeutics, INC. | $509.80 | 2024-2025 | Daxxify, Daxi |
| Medtronic, INC. | $406.10 | 2022-2025 | Percept Pc Brainsense, Sensight |
| Ucb, INC. | $386.76 | 2019 | |
| Avanir Pharmaceuticals, INC. | $319.29 | 2019-2022 | |
| Merz North America, INC. | $281.75 | 2019-2020 | |
| Supernus Pharmaceuticals, INC. | $215.84 | 2022-2025 | Qelbree |
| Boston Scientific Corporation | $190.83 | 2019-2023 | |
| Ipsen Biopharmaceuticals, INC | $158.59 | 2019-2022 | |
| Axsome Therapeutics, INC. | $154.40 | 2024-2025 | Auvelity |
| Otsuka America Pharmaceutical, INC. | $133.79 | 2023-2024 | Nuedexta |
| Lundbeck LLC | $126.46 | 2019-2025 | Rexulti |
| Avion Pharmaceuticals | $107.49 | 2022-2023 | Dhivy |
| Eisai INC. | $89.90 | 2023-2024 | |
| Azurity Pharmaceuticals, INC. | $79.25 | 2023-2024 | Horizant, Horizant |
| Alexion Pharmaceuticals, INC. | $28.24 | 2023 | Ultomiris |
| Xeris Pharmaceuticals, INC. | $23.73 | 2023 | Keveyis |
| Impel Pharmaceuticals INC. | $21.29 | 2022 | |
| Arbor Pharmaceuticals, INC. | $15.16 | 2019 | |
| Emd Serono, INC. | $12.01 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yasar Torres-Yaghi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.